Eli Lilly Raises 2025 Forecast as Zepbound and Mounjaro Fuel Explosive Growth
- Eli Lilly has upgraded its full-year guidance after reporting explosive demand for its weight-loss drugs Zepbound and Mounjaro. The company’s third-quarter results showed a sharp revenue increase, fueled by consumer uptake of its GLP-1 treatments.
- To further scale distribution, Lilly announced a new partnership with Walmart that will make Zepbound available for pickup at pharmacy locations nationwide. The move is expected to expand access and reinforce Lilly’s dominance in the obesity drug market.
Key Takeaways
Eli Lilly Lifts Forecast as Mounjaro and Zepbound Smash Sales Expectations
Eli Lilly’s third-quarter earnings surged on the back of explosive demand for its weight-loss drugs Mounjaro and Zepbound. The company posted adjusted earnings of $7.02 per share, beating analyst expectations of $5.91. Revenue jumped 54% year-over-year to $17.6 billion, far exceeding the $16.06 billion forecast.
Mounjaro sales more than doubled to $6.52 billion, while Zepbound nearly tripled to $3.59 billion both outperforming Wall Street projections. The strength of Lilly’s GLP-1 portfolio continues to reshape the obesity drug market and drive investor confidence in its long-term growth trajectory.
Why Eli Lilly’s Weight-Loss Drug Boom Signals Long-Term Market Power
Eli Lilly’s latest earnings reflect a seismic shift in the pharmaceutical landscape. With Zepbound and Mounjaro driving record sales and new distribution deals like its Walmart partnership expanding access, the company is cementing its dominance in the GLP-1 weight-loss drug category.
Analysts expect the global obesity treatment market to reach tens of billions in value over the next few years. Lilly’s aggressive scaling and product momentum position it as a frontrunner in capturing that growth, making its stock a focal point for long-term healthcare investors.
Eli Lilly Ups Forecast and Expands Zepbound Access via Walmart Deal
Eli Lilly raised its full-year revenue guidance to $63 $63.5 billion, up from its previous range of $60 $62 billion. The company also boosted its adjusted EPS outlook to $23 $23.70, reflecting confidence in sustained demand for its GLP-1 weight-loss treatments.
To widen access, Lilly announced a new partnership with Walmart that will allow patients to pick up Zepbound at pharmacy locations starting mid-next month. The move is expected to accelerate retail distribution and reinforce Lilly’s market position.
Shares of Eli Lilly rose 2% in recent trading. Year-to-date, the stock is up about 5%, trailing the S&P 500’s 17% gain, as investors weigh growth potential against broader market momentum.
